Voyager selects lead candidate for SOD1-ALS gene therapy; IND filing expected mid-2025

Voyager Therapeutics, Inc.

Lead candidate combines siRNA construct with IV-delivered TRACER capsid targeting SOD1-mutated ALS.
Non-human primate study showed 73% reduction of SOD1 in cervical spinal cord motor neurons after single IV dose.
Another preclinical candidate previously increased survival by median 152 days in G93A mouse model.
Additional candidate data to be presented at upcoming scientific conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.